Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies

Samankaltaisia teoksia

• The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea
  Tekijä: Johnson, Andrew William, et al.
  Julkaistu: (2015)
• The role of brimonidine tartrate gel in the treatment of rosacea
  Tekijä: Jackson, J Mark, et al.
  Julkaistu: (2015)
• Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability
  Tekijä: Anderson, Michael S, et al.
  Julkaistu: (2017)
• Brimonidine gel 0.33% rapidly improves patient‐reported outcomes by controlling facial erythema of rosacea: a randomized, double‐blind, vehicle‐controlled study
  Tekijä: Layton, A.M., et al.
  Julkaistu: (2015)
• Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies
  Tekijä: Holmes, Anna D., et al.
  Julkaistu: (2015)